While in the hospital, she showed no insight and felt that there was nothing wrong. She wanted to walk nude, arguing that there are nude beaches in the world, and therefore, nudity should be acceptable in the psychiatric unit. She refused to take any medication, again claiming that there was nothing wrong with her. She became hostile, and I had to use intramuscular benzodiazepine treatment. Her Young Mania Rating Scale (YMRS) score was 48, which is consistent with severe mania. She was started back on gabapentin and also received risperidone liquid 1 mg twice daily. After 2 doses of risperidone, which were administered with difficulty, she showed a dramatic response. Her psychomotor excitement and inappropriate sexual behaviours totally disappeared, and she started to sleep well. Two days later, her YMRS score was was 17.
Although antipsychotics are frequently used to control psychotic agitation, risperidone was found to be unique in this case. Certainly, it stabilized her mood within a couple of days and with only 2 doses. Given this case report, it may be wise to consider risperidone liquid as a first choice in the case of acute mania, in addition to any other mood stabilizer. I reviewed with interest the case report in your journal describing unexpected grand mal seizures in a 14-year-old boy treated for attention-deficit hyperactivity disorder (ADHD) with methylphenidate (MPH) 60 mg daily, to which buproprion was added (1). The author notes, "it is also possible that the risk of seizures was amplified by the combination of buproprion and methylphenidate" (1, p 790).
This case report is of concern, insofar as a combination of buproprion and MPH, if known to be safe, would be a sensible augmented regimen for treatmentresistant or treatment-refractory cases of ADHD (2) and perhaps even depressive disorders (3).
However, the literature suggests a mechanism for possible deleterious interaction between these 2 agents; namely, it is possible that MPH inhibits a hepatic isoenzyme that contributes to the metabolic clearance of buproprion from the body. Several authors have alluded to methylphenidate's capacity to inhibit the degradation of cyclic antidepressants (4) (5) (6) . MPH has been cited as an inhibitor of CYP2D6 (7) . It may also inhibit other hepatic enzymes, including perhaps CYP2B6, the isoenzyme predominantly responsible for the metabolism of buproprion (8), or other enzymes not currently known to help clear buproprion.
The net result of such a possible interaction could be higher buproprion plasma levels and greater risk of seizure. This risk may be compounded by buproprion's own inherently greater epileptogenic potential and the rapidity of its time to peak levels in both the older formulation and the newer slow release (SR) compound (9). It has been theorized that "rapidity of dose escalation" is a factor in the capacity for antidepressants to cause seizure (10). Peak plasma level occurs within 2 hours for buproprion (traditional preparation) and within 3 hours for the newer SR preparation after oral ingestion. This is 2 to 3 times faster than, for example, "time to peak plasma level" for fluoxetine, which requires 6 to 8 hours (9). By reducing metabolic clearance, a coadministered hepatic enzyme inhibitor such as MPH may accelerate time to peak and also amplify peak plasma concentrations, both of which have been implicated as risks in buproprioninduced seizures (10). Aggressive and hostile behaviours can be manifestations of schizophrenia, among other mental disorders (for example, mood disorders and dementia) (1) and contribute considerably to institutionalization (2) . In patients with chronic schizophrenia, clozapine treatment has resulted in a selective improvement in aggressive behaviour, beyond the global improvement shown on the Brief Psychiatric Rating Scale (BPRS) (3, 4) , although this improvement did not necessarily extend to the positive symptoms of psychosis (5). Risperidone treatment showed a greater selective effect on hostility in schizophrenia patients than did haloperidol or placebo (6), although there are some contradictory data from an open trial comparing risperidone and haloperidol (7) . In clinical practice, risperidone has proven very useful in treating aggression and violence in patients with chronic refractory schizophrenia (8). In a case series, olanzapine had better, but not significantly different, tranquilizing properties after 3 days of treatment, compared with haloperidol (9). Quetiapine in high dosages (up to 900 mg daily) was used successfully in 2 treatment-resistant patients with schizophrenia and concomitant aggression (10,11). In the first instance, quetiapine was added to divalproex sodium (10), and in the second, it was coadministered with risperidone (11).
In this report, we describe the case of a patient with an unremitting acute psychotic episode whose hostility and aggressive symptoms improved soon after he was given combined quetiapine and risperidone.
Case Report
A 35-year-old, unmarried man was involuntarily admitted to our clinic. He showed auditory hallucinations, delusions of persecution and reference, aggressiveness, psychomotor agitation, and restricted affect. He appeared markedly dishevelled. His score on the Brief Psychiatric Rating Scale (BPRS), in which each item is rated 1 to 7, was 57; on tension, hostility, and agitation he had a score of 6 (severe). His psychiatric problems started about 3 years ago, when he stopped working and showed total social isolation, wandering, and untriggered and unpredictable verbal outbursts. He refused any psychiatric treatment and was diagnosed with schizophrenia, paranoid type, according to DSM-IV criteria.
He refused medication and was therefore given haloperidol 30 mg daily intramuscularly for 5 days. When he subsequently consented to take medication, risperidone was gradually added while the dosage of haloperidol was slowly tapered. After 20 days, his regimen consisted only of risperidone 12 mg daily. However, he did not show any sign of improvement, and any effort to stop restraint failed. As a result, after 1 week of risperidone monotherapy, quetiapine was added and titrated to 500 mg daily in 5-day intervals. When he was evaluated 1 week later, he showed marked improvement in symptoms, scoring 36 on the BPRS; on hostility and tension, he scored 2 (very mild), and on agitation, 3 (mild). After about 40 days of hospitalization the patient was released from restriction, and 2 weeks later, he was discharged from our clinic. His risperidone was decreased to 8 mg daily; no change was made in his daily quetiapine dosage. One month after discharge, his clinical state remains the same, with no
